Financial Architects, Inc Mannkind Corp Transaction History

Financial Architects, Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 14, 2019	SELL	$1.09 - $1.88 $65 - $112	-60 Closed	0 $0
Q1 2019 May 13, 2019	BUY	$1.14 - $2.25 $68 - $135	60 New	60 $0
Q1 2019 May 03, 2019	SELL	$1.14 - $2.25 $68 - $135	-60 Closed	0 $0
Q2 2018 Aug 03, 2018	SELL	$1.59 - $2.38 $31 - $47	-20 Reduced 25.0%	60 $0
Q4 2017 Feb 12, 2018	SELL	$2.28 - $6.71 $2,280 - $6,710	-1,000 Reduced 92.59%	80 $0
Q3 2017 Nov 01, 2017	BUY	$1.15 - $2.29 $1,242 - $2,473	1,080	1,080 $2,000

245

148M

1.62M

802K

Ticker MNKD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 257,338,000
Market Cap $1.73B
Description
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocri...

Get notified when there are updates to the investment portfolio of Financial Architects, Inc, based on Form 13F filings with the SEC.

Stay updated on Financial Architects, Inc with notifications on news.